BTK (Y485F)
Sign in to save this workspaceBTK · Variant type: point · HGVS: p.Y485F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pirtobrutinib | 99.1% | 0.9% | 99.49 |
| 2 | Canertinib | 96.5% | 3.5% | 96.49 |
| 3 | Mobocertinib | 95.5% | 4.5% | 97.22 |
| 4 | Entrectinib | 94.5% | 5.5% | 93.69 |
| 5 | Zanubrutinib | 94.1% | 5.9% | 98.24 |
| 6 | Repotrectinib | 92.1% | 7.9% | 84.21 |
| 7 | Acalabrutinib | 91.9% | 8.1% | 99.50 |
| 8 | Remibrutinib | 90.4% | 9.6% | 99.50 |
| 9 | Neratinib | 87.7% | 12.3% | 93.18 |
| 10 | Vandetanib | 85.4% | 14.6% | 95.74 |
| 11 | Pacritinib | 80.9% | 19.1% | 88.64 |
| 12 | Gilteritinib | 80.0% | 20.0% | 88.97 |
| 13 | Pralsetinib | 71.6% | 28.4% | 93.43 |
| 14 | Alpelisib | 60.0% | 40.0% | 97.22 |
| 15 | Pemigatinib | 53.2% | 46.8% | 98.23 |
| 16 | Lazertinib | 50.4% | 49.6% | 97.47 |
| 17 | Sunitinib | 47.0% | 53.0% | 91.73 |
| 18 | Erdafitinib | 40.6% | 59.4% | 95.71 |
| 19 | Futibatinib | 39.2% | 60.8% | 98.48 |
| 20 | Fedratinib | 36.0% | 64.0% | 96.21 |
| 21 | Darovasertib | 30.3% | 69.7% | 96.99 |
| 22 | Paxalisib | 28.4% | 71.6% | 99.75 |
| 23 | Tenalisib | 26.3% | 73.7% | 97.98 |
| 24 | Erlotinib | 23.8% | 76.2% | 99.75 |
| 25 | Avapritinib | 20.6% | 79.4% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pirtobrutinib | 99.1% | 97.7% | +1.4% |
| Canertinib | 96.5% | 99.3% | -2.8% |
| Mobocertinib | 95.5% | 97.4% | -1.9% |
| Entrectinib | 94.5% | 95.1% | -0.6% |
| Zanubrutinib | 94.1% | 97.4% | -3.3% |
| Repotrectinib | 92.1% | 93.7% | -1.6% |
| Acalabrutinib | 91.9% | 95.9% | -4.0% |
| Remibrutinib | 90.4% | 97.7% | -7.3% |
| Neratinib | 87.7% | 93.9% | -6.2% |
| Vandetanib | 85.4% | 83.8% | +1.7% |
| Pacritinib | 80.9% | 80.3% | +0.6% |
| Gilteritinib | 80.0% | 87.6% | -7.6% |
| Pralsetinib | 71.6% | — | — |
| Alpelisib | 60.0% | — | — |
| Pemigatinib | 53.2% | — | — |
| Lazertinib | 50.4% | — | — |
| Sunitinib | 47.0% | — | — |
| Erdafitinib | 40.6% | — | — |
| Futibatinib | 39.2% | — | — |
| Fedratinib | 36.0% | — | — |
| Darovasertib | 30.3% | — | — |
| Paxalisib | 28.4% | — | — |
| Tenalisib | 26.3% | — | — |
| Erlotinib | 23.8% | — | — |
| Avapritinib | 20.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| chronic_lymphocytic_leukemia | Blood/Lymphatic System | ref |
| anaplastic_large_cell_lymphoma | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.8ms